SciVac, which is partially owned by Opko Health, Inc., recently became a public entity and began trading on the Toronto Stock Exchange.
Dr. Phillip Frost, the chairman and CEO of Opko Health, reportedly wanted to restructure the privately held SciVac. The company's main product is Sci-B-Vac, a third-generation hepatitis B vaccine approved for use in 10 countries and already administered to more than 500,000 patients in these regions.
Under a deal that was finalized on July 10 and included Levon Resources Ltd., a gold and precious metals exploration company, Opko received more than 30 percent of the company's outstanding common shares while its remaining owners received 68.4 percent of the shares.
With Sci-B-Vac showing promise and Frost bringing a number of institutional and individual investors along as followers, analysts are predicting a bright future for the newly listed SciVac
